RxDoctor Payments Data

Jaime Square, MD

Internal Medicine · El Paso, TXNPI 1205046752

Payments from drug & device makers

$771in general payments, 2019–2025

Across 28 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Revance Therapeutics, Inc.$332
  • Misonix Inc$119
  • Pfizer$80
  • Abbott$45
  • GSK$29
  • Corcept Therapeutics$24
  • plus $141 from 9 others

What the payments were for

  • Food & beverage$771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$771 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$163,753
Medicare patients
333
Services billed
2,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$129,602
EliquisApixaban229$89,242
JanuviaSitagliptin Phosphate111$76,008
TrulicityDulaglutide31$53,112
FarxigaDapagliflozin Propanediol39$46,142
IngrezzaValbenazine Tosylate12$46,048
JardianceEmpagliflozin34$26,169
MounjaroTirzepatide12$21,818
TradjentaLinagliptin49$16,621
LinzessLinaclotide16$15,280
XifaxanRifaximin11$15,269
VraylarCariprazine Hcl18$12,432
RexultiBrexpiprazole18$11,539
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,290
XareltoRivaroxaban35$9,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$129,60299 claims
PfizerEliquis$80$89,242229 claims
Lilly USA, LLCTrulicity, Mounjaro$15$74,93043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →